Recent Finacing
Recent Raise
Ribonexus develops oncology therapies that restore sensitivity to targeted treatments in resistant tumors, advancing an eIF4A inhibitor for melanoma, expanding indications and partnering with Pierre Fabre.
Focus Areas
Recent Investors
Total Raised
Funding round
Investor
See the team members at Ribonexus.
